Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Gives Direction On Pegfilgrastim And Ranibizumab

Neulasta Biosimilar Previously Slated For FY2021

Executive Summary

Indian major Lupin is continuing to further efforts on its three main growth drivers: biosimilars, inhalation products and long-acting injectables, management told the virtual J.P. Morgan Healthcare Conference in San Francisco.

You may also be interested in...



Sun Gets CGT Nod For AmBisome Rival

Sun Pharma is looking to target a market worth $136m after receiving US FDA approval for amphotericin B liposome with a Competitive Generic Therapy designation, bringing the promise of 180 days of CGT exclusivity for the product.

Lupin Gets Another First With Fostair

Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.

Lupin Expects Respiratory Ramp Up From Fiscal '22

After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel